COMMUNIQUÉS West-GlobeNewswire

Fagron increases share capital through exercise subscription rights
31/03/2026
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 31 March 2026 – 7PM CET Fagron increases share capital through exercise subscription rights Fagron announces that as a result of the exercise of [...]
Serenity Medical Receives U.S. FDA HDE Approval of the River™ Stent - the First Venous Stent Approved for Severe, Refractory Idiopathic Intracranial Hypertension (IIH)
31/03/2026
Landmark regulatory milestone makes the River stent available for adults with severe IIH – a debilitating, historically undertreated condition – who have failed medical therapy Serenity Medical partners with Radical [...]
UPDATE - Lumina Therapy Alliance Expands National Footprint with Addition of The Therapy Group of DC, Reaching Nearly 400 Clinicians Nationwide
31/03/2026
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Lumina Therapy Alliance , a growing national network of premier, in-person mental health practices, today announced that The Therapy Group of DC has joined its alliance. With [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
31/03/2026
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 31 March 2026 at 18:00 EEST Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
Stage4Hope™ Commits $2.5 Million to Memorial Sloan Kettering Cancer Center to Accelerate Breakthrough Cancer Research
31/03/2026
Nonprofit founded by Stage IV lung cancer patient supports precision oncology research aimed at expanding treatment options for advanced cancers ATLANTA, March 31, 2026 (GLOBE NEWSWIRE) -- Stage4Hope™ , a nonprofit [...]
Indiana Overdose Deaths Drop 18% But Deadly New Substances Threaten to Reverse Progress
31/03/2026
The "State of Addiction in Indiana" report highlights significant progress and emerging challenges in the state's battle against addiction. Indianapolis, INDIANA, March 31, 2026 (GLOBE NEWSWIRE) -- Indiana Rehabs has [...]
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
31/03/2026
Fort Lee, NJ, March 31, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision [...]
Catheter Precision Reports 2025 Results and Updates on Strategic Expansion
31/03/2026
Clinical, Commercial and Regulatory Milestones Achieved in 2025 Establish a Strong Foundation in Life Sciences as Revenue Increases 95% Year Over Year Acquisition of Flyte and Strengthened Capital Position Unlock Multi- [...]
IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study
31/03/2026
IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with advanced ovarian cancer Final Phase 2 clinical data show [...]
Proxygen Appoints Chiara Conti, Ph.D. as Chief Scientific Officer to Drive Clinical Translation and Expand Induced Proximity Platform Beyond Degradation
31/03/2026
Vienna, Austria, March 31, 2026 (GLOBE NEWSWIRE) -- Vienna, Austria, March 31, 2026 - Proxygen, a biotechnology company pioneering the discovery of molecular glue degraders and next-generation proximity-based [...]
Adcytherix Doses First Patient in Phase 1 Trial of ADCX-020 and Strengthens Leadership to Support Next Phase of Growth
31/03/2026
Adcytherix Doses First Patient in Phase 1 Trial of ADCX-020 and Strengthens Leadership to Support Next Phase of Growth Initial patient dosed in the First-in-Human clinical trial of ADCX-020, marking Adcytherix’s [...]
electroCore Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
31/03/2026
ROCKAWAY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Seth Abrams will join [...]
PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA
31/03/2026
PolyPid Submits First Modules as Part of Rolling NDA Review; Completion expected in Second Quarter of 2026 U.S. Commercialization Partnership Negotiations on Track PETACH TIKVA, Israel, March 31, 2026 (GLOBE NEWSWIRE [...]
Vantive Presents New Data at WCN on How Coordinated Care Ecosystems Can Expand Home-Based Peritoneal Dialysis Access and Improve Patient Outcomes
31/03/2026
Nephroprotection and early intervention support more planned dialysis starts, improved patient outcomes and increased use of home therapies, according to new studies. Real-world studies also evaluate a unique care [...]
Onconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of Directors
31/03/2026
Experienced Leadership Team Positioned to Execute Pending Transformative Acquisition of Realbotix LLC and Drive Long-Term Shareholder Value CINCINNATI, Ohio, March 31, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: [...]
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
31/03/2026
SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant [...]
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
31/03/2026
Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028 Received FDA Fast Track designation for stenoparib, enabling accelerated [...]
Iantrek Advances New AlloSpan™ Canal into U.S. Site Evaluations, Expanding Its Bio-Interventional Platform
31/03/2026
Controlled early clinical adoption begins across select U.S. centers as Iantrek accelerates toward commercialization of its next-generation canal-based restoration technology WHITE PLAINS, N.Y., March 31, 2026 (GLOBE [...]
Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease
31/03/2026
– A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission – IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS [...]

Pages